This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

NPS Pharma Buys Back Worldwide Rights To Short Bowel Syndrome Drug

Stocks in this article: NPSPALXNBMRN

BEDMINSTER, NJ ( TheStreet) -- NPS Pharmaceuticals (NPSP) has reacquired worldwide marketing rights to two approved drugs, most notably its short bowel syndrome therapy Revestive, from Takeda.

Under terms of the re-worked deal, Takeda will receive $50 million in NPS Pharma stock in exchange for relinquishing ex-North America commercial rights to Revestive and Preotact, a thyroid hormone replacement therapy. NPS partnered with Nycomed for Preotact in 2004 and Revestive in 2007, and then Takeda acquired Nycomed in 2011.

The drugs were sold back to NPS Pharma because they are no longer "strategic" to the company, according to spokesman Tobias Cottman.

European regulators approved Revestive last August but Takeda had not yet launched the drug. That responsibility will now fall to NPS Pharma, which needs to build out a commercial operation in Europe while also remaining focused on selling the drug in the U.S., where it's known as Gattex.

NPS Pharma has brought on a former Genzyme sales executive as a consultant to help in Europe. Revestive pricing, reimbursement and a specific launch timetable for individual European countries have not been decided, said CEO Francois Nader.

Nader says he approached Takeda about re-acquiring rights to Revestive and Preotact because he wants NPS Pharma to have worldwide commercial rights to its orphan drug products, similar to Alexion Pharmaceuticals (ALXN), Biomarin Pharmaceuticals (BMRN) and Genzyme unit of Sanofi (SNY).

But before NPS Pharma can join those peers, the company will need to prove that it can sell Gattex/Revestive worldwide. That Takeda agreed to relinquish two drugs for little more than $50 million in stock will inevitably raise some doubts.

Investors have already been in "show me" mode when it comes to NPS Pharma. At $9 per share, NPS Pharma's stock price hasn't budged since FDA approved Gattex in January and the company decided to price a single year of therapy at almost $300,000. NPS Pharma justifies ultra-orphan pricing for Gattex because there are only a few thousand patients in the U.S. who suffer from short bowel syndrome -- a debilitating condition that makes patient dependent on intravenous parenteral nutrition. Critics say Gattex may be hard-pressed to justify its high cost because for most patients, the drug only reduces the need for IV feeding but doesn't eliminate it entirely.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,390.52 +195.10 1.13%
S&P 500 0.00 -2.75 -0.14%
NASDAQ 4,630.7410 +64.6030 1.41%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs